Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation

J Heart Lung Transplant. 1999 Aug;18(8):814-7. doi: 10.1016/s1053-2498(99)00038-8.

Abstract

Vasodilatory hypotension requiring the administration of catecholamine pressors may occur following cardiopulmonary bypass. We investigated the hemodynamic response to arginine vasopressin (AVP) in 20 patients who developed vasodilatory hypotension after cardiac transplantation. In this cohort, AVP infusion (0.1 U/min) significantly increased mean arterial pressure and decreased norepinephrine requirements, allowing rapid discontinuation of norepinephrine infusions in 7 patients. Judicious use of this novel agent in appropriately selected patients may minimize end-organ sequelae of hypotension and high-dose catecholamine therapy.

Publication types

  • Comparative Study

MeSH terms

  • Arginine Vasopressin / administration & dosage
  • Arginine Vasopressin / therapeutic use*
  • Blood Pressure / drug effects
  • Cardiopulmonary Bypass / adverse effects
  • Female
  • Heart Transplantation / adverse effects*
  • Humans
  • Hypotension / drug therapy*
  • Hypotension / etiology
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Treatment Outcome
  • Vascular Resistance / drug effects
  • Vasoconstrictor Agents / administration & dosage
  • Vasoconstrictor Agents / therapeutic use*
  • Vasodilation / drug effects*

Substances

  • Vasoconstrictor Agents
  • Arginine Vasopressin